<DOC>
	<DOCNO>NCT02224547</DOCNO>
	<brief_summary>The purpose study perform prospective data analysis tumor response term local tumor control 2 year , potential acute late toxicity survival patient non-metastatic , non-small-cell lung cancer treat radiotherapy medically inoperable due coexist comorbidities refuse surgery . SBRT regimens use 4 fraction 12 Gy 3 fraction 17 Gy depend tumor location risk-adapted approach .</brief_summary>
	<brief_title>Risk-adapted Stereotactic Body Radiotherapy Early Non-Small Cell Lung Cancer Using VERO Stereotactic Body Radio Therapy System</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Stage T1 , T2 , T3N0M0 NSCLC , histological confirmation either biopsy cytology 2 . Maximal tumor diameter 6 cm 3 . Only T3 lesion base upon thoracic wall involvement , 1 lesion 4 . Informed consent require 5 . Life expectancy least 6 month 6 . Age &gt; /= 18 . 7 . Karnofsky score ≥ 70 ECOG score ≤ 2 8 . Inoperable patient patient refuse surgery 9 . Patients measurable lesion ( accord RECIST criterion ) 1 . Diagnosis small cell lung cancer 2 . Lymph node involvement 3 . Prior radiotherapy chest and/or mediastinum 4 . No chemotherapy and/or target treatment within 3 month SBRT 5 . Pregnant lactate woman 6 . Known allergy CT contrast 7 . No FDGPET 8 . Mental condition render patient unable understand nature , scope , possible consequence study . 9 . Patient unlikely comply protocol , i.e. , uncooperative attitude , inability return followup visit , extreme degradation lung function test patient likely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>lung carcinoma</keyword>
	<keyword>NSCLC</keyword>
</DOC>